NCT07882732Not yet recruiting
RPM Signals in Outpatient CAR T Therapy
Characterizing Remote Patient Monitoring Signals During Outpatient CAR T Therapy: A Prospective Observational Cohort Study
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
The goal of this observational study is to learn how patients' vital signs and symptoms change during outpatient CAR T-cell therapy with lisocabtagene maraleucel (liso-cel), a type of cancer treatment. The study tracks vital signs and other health data at home using wearable monitoring devices. It includes adults with blood cancers who are receiving liso-cel as outpatients, meaning they are at home rather than staying in the hospital during treatment. The main questions it aims to answer are: * What do patients' vital signs and monitoring data look like from 3 days before through 14 days after their CAR T-cell infusion, and what side effects do they experience, such as cytokine release syndrome (a fever and inflammation reaction) and neurological side effects? * How are patients' individual characteristics and monitoring data related to these side effects? Participants will: * Use the Current Health home monitoring kit, including a wearable device that tracks breathing rate, pulse, oxygen levels, skin temperature, and step count, plus a blood pressure cuff, a temperature patch, a thermometer, a tablet, and a device that sends data without needing home internet. Monitoring starts 3 days before infusion and continues for 14 days afterward, pausing during any hospital stays. * Answer short questions about their experience on the tablet. * Continue their regular medical care and appointments. The study team will collect information from their medical records, such as test results, treatment details, and any side effects or complications. Participants receive CAR T-cell therapy as part of their regular care. The study does not test or change any treatment. Researchers are only observing and recording what happens during this at-home care model.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 125 (estimated)
- First submitted
- 29 Sept 2026
- Start date
- 1 Dec 2026
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- Current Health
- Diseases
- Chronic lymphocytic leukaemia
- NCT number
- NCT07882732
What you commit to
- Study type: Observational
- Planned participants: 125
- From 1 Dec 2026 to the primary completion date, 1 Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age under 18 years
Other
- Inability or unwillingness to provide informed consent
- Inpatient admission planned at time of enrollment
- Any contraindication to use the Current Health wearable device as listed by the device manufacturer in the device Instructions For Use.
- Participation in another interventional study that would confound study outcomes, unless approved by both studies' principal investigators.
Who the study is looking for
- Patients scheduled to receive liso-cel as an outpatient for a hematologic malignancy at a participating institution
- Meet the participating institution's outpatient CAR T program's eligibility criteria
- Able to use and return the monitoring device
- English- or Spanish-speaking and willing to use the interpreter services available via the platform if needed
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.